Ivermectin B1b

CAT: 0804-HY-125729-01Size: 500 µgDry Ice: NoHazardous: No
CAT#:0804-HY-125729-01Size:500 µg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ivermectin B1b is the minor component of Ivermectin. Ivermectin, a potent anti-parasitic agent, inhibits the replication of SARS-CoV-2 in cell culture[1][2].
CAS Number
[70209-81-3]
UNSPSC
12352005
Target
Parasite; SARS-CoV
Type
Natural Products
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/ivermectin-b1b.html
Purity
98.66
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC([C@H]1O[C@]2(CC[C@@H]1C)C[C@](O3)([H])C[C@](C/C=C([C@H]([C@H](/C=C/C=C4[C@@]5(O)[C@](C=C(C)[C@@H](O)[C@@]5([H])OC/4)([H])C3=O)C)O[C@@]6([H])C[C@@H]([C@@H](O[C@@]7([H])C[C@@H]([C@@H](O)[C@H](C)O7)OC)[C@H](C)O6)OC)\C)([H])O2)C
Molecular Formula
C47H72O14
Molecular Weight
861.07
References & Citations
[1]Katz N, et al. Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of Schistosomiasis. J Antibiot (Tokyo) . 2017;70 (5) :680-684.|[2]Bray M, et al. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res. 2020;178:104805.|[3]Demeler J, et al. Measuring the effect of avermectins and milbemycins on somatic muscle contraction of adult Haemonchus contortus and on motility of Ostertagia circumcincta in vitro. Parasitology. 2014;141 (7) :948-956.|[4]Collins T, et al. Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator. Mol Pharmacol. 2010;78 (2) :198-204.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported

Alternative Products

Popular Products